BridgeMD
New treatment option for Fungal Keratitis
Official title Fungal Ulcer Treatment Augmented With Natamycin and Cyclosporine A
ClinicalTrials.gov ID: NCT06658002
What this study is testing
What is Cyclosporine A?
Cyclosporine A is an investigational medicine, given as a treatment applied to the skin, being studied as a potential treatment for fungal keratitis.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The goal of this clinical trial is to learn if adjunctive topical Cyclosporine A eye drops combined with standard of care topical Natamycin treatment improves vision outcomes in patients with fungal keratitis.
- Phase 3: a large, late-stage study
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Inclusion is based on presenting acuity, not ulcer size.
- Inclusion of 20/40 = 6/12 = 0.3 Log MAR and 20/400 = 3/60 = +1.3 Log MAR.
- Smear or culture positive for fungal keratitis, any length.
- Age 18 years.
- Willing to participate in study.
You likely can't join if
- Co-infection with bacterial or viral keratitis.
- Corneal perforation.
- Requiring therapeutic keratoplasty for fungal keratitis.
- Unwilling or unable to follow up (e.g., living too far from hospital).
- Presenting acuity better than 20/40 = 6/12 = 0.3 Log MAR or worse than 20/400 = 3/60 = +1.3 Log MAR.
- people taking cyclosporine at any concentration on presentation.
See the full eligibility criteria
- Inclusion is based on presenting acuity, not ulcer size.
- Inclusion of 20/40 = 6/12 = 0.3 Log MAR and 20/400 = 3/60 = +1.3 Log MAR.
- Smear or culture positive for fungal keratitis, any length.
- Age 18 years.
- Willing to participate in study.
- Co-infection with bacterial or viral keratitis.
- Corneal perforation.
- Requiring therapeutic keratoplasty for fungal keratitis.
- Unwilling or unable to follow up (e.g., living too far from hospital).
- Presenting acuity better than 20/40 = 6/12 = 0.3 Log MAR or worse than 20/400 = 3/60 = +1.3 Log MAR.
- people taking cyclosporine at any concentration on presentation.
- Acuity worse than 20/200 = 6/60 = +1.0 Log MAR in unaffected eye.
- Pregnant women.
- Penetrating Keratoplasty.
- Presents with a 0-7 day history of topical steroid.
The study team makes the final eligibility decision.
Where it's taking place
- San Francisco, California, United States
- Pondicherry, Tamil Nadu, India
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include San Francisco, California, United States; Pondicherry, Tamil Nadu, India. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.